2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2406

Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics
Abstract Number: 2548

Primary Sjögren’s Syndrome Is Associated with Significant Cognitive Dysfunction
Abstract Number: 968

Priming of WNT Signalling during Fibrosis Is Mediated By TGF-β Induced Axin-2 Downregulation
Abstract Number: 2874

Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity
Abstract Number: 34

Pro-Nerve Growth Factor (ProNGF) Stimulates Bone Growth By Stimulating Osteoblasts and Inhibiting Osteoclast Differentiation, an Explanation for Anti-NGF-Mediated Osteonecrosis; Prongf Is a Novel Therapeutic Target for Treatment of Osteonecrosis and Charcot’s Arthropathy
Abstract Number: 1667

Probability of 3 and 6 Month Complete Response in Lupus Nephritis
Abstract Number: 1807

Problems with Fee for Service Payments for Academic Rheumatology Practices: A Need for Payment Reform:
Abstract Number: 1988

Process Outcomes and Community-Wide Efficacy of the Amigo Inter-Institutional Mentoring Initiative within Pediatric Rheumatology
Abstract Number: 2569

Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab
Abstract Number: 1975

Profiling 14-3-3η in Human Primary Cell Based BioMAP^® Disease Models Reveals a Unique Pro-Inflammatory Phenotypic Signature Consistent with RA-Inflammation Biology
Abstract Number: 1606

Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity
Abstract Number: 2605

Profiling Ankylosing Spondylitis Patients Likely to Respond to NSAID Treatment
Abstract Number: 830

Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Abstract Number: 812

Prognosis of Clinically Inactive Takayasu’s Arteritis
Abstract Number: 1784

Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].